MedPath

Phase II study of efficacy and safety of duloxetine for chlonic oxaliplatin-induced peripheral neuropathy in metastatic colorectal cancer

Phase 2
Recruiting
Conditions
advanced colorectal cancer
Registration Number
JPRN-UMIN000010621
Lead Sponsor
Osaka City General Hospital Department of Clinical Oncology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1)having other active malignancies 2) severe complications (uncontrolled diabetes mellitus, interstitial lung disease, pulmonary fibrosis, heart failure ,renal failure, hepatic failure, etc.) 3) having active infections 4) history of severe drug hypersensitivity 5) uncontrollable serious mental problem 7) pregnant or female intend to be pregnant, and male intend to make pregnant. 8) peripheral neuropathy>=Gr2 9)Others

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
prolongation of period of oxaliplatin treatment
Secondary Outcome Measures
NameTimeMethod
safety
© Copyright 2025. All Rights Reserved by MedPath